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Available online 8 May 2016The phosphatidylinositol 3-kinase (PI3K) pathway is known to down-regulate inﬂammatory cytokine responses
in dendritic cells andmacrophages stimulatedwith TLR agonists. This is due to class I PI3Ks causing the activation
of Akt, which in turn inactivates GSK3, a kinase that promotes the transcription of IL-12 and represses that of anti-
inﬂammatory IL-10. Using bonemarrow-derived dendritic cells we ﬁnd thatwhereas pharmacological inhibition
of Akt or GSK3 has the expected effects on these cytokines, the widely used PI3K inhibitor wortmannin causes a
paradoxical increase in the production of IL-10. Wortmannin inhibits all PI3K classes, including PI3K class III, in-
volved in endosomal function and autophagy, for which speciﬁc inhibitors were until recently not available.
Using inhibitors speciﬁc for PI3K class III vs class I, we show that whereas inhibition of class I PI3K has the expect-
ed opposing effects on IL-10 and IL-12 production, inhibition of class III PI3K enhances the production of both of
these, plus further cytokines. This explains the paradoxical inhibition of IL-10 production by wortmannin.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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IL-101. Introduction
The phosphoinositide 3-kinase (PI3K) enzyme family is involved in
several central aspects of cell and tissue biology, including cell survival
and proliferation, metabolism, autophagy, and inﬂammation. All PI3Ks
are composed of a C2 domain, a helical domain, and a catalytic domain
[1]. The PI3K classiﬁcation depends on the presence of additional pro-
tein domains, their interactions with regulatory subunits, and the 3-
phosphorylated phosphoinositides that they synthesise. Class I PI3Ks
are formed by four different catalytic subunit isoforms, namely PI3Kα,
PI3Kβ, PI3Kγ andPI3Kδ, which heterodimerisewith different regulatory
subunits. There are three isoforms of class II PI3K, namely PI3KC2α,
PI3KC2β and PI3KC2γ. Lastly, there is only one catalytic subunit of
class III PI3K called VPS34 (vacuolar protein sorting 34).
Class I PI3Ks generate phosphatidylinositol (3,4,5)-triphosphate,
PI(3,4,5)P3 [1]. One of the main effectors of class I PI3Ks is the kinase
Akt (PKB). Akt is recruited to membranes by PI(3,4,5)P3, where it is
phosphorylated by PDK-1 (on T308) and mTORC2 (on S473) for its
complete activation [2]. This PI3K/Akt pathway regulates cell survival,uilding, Faculty of Life Sciences,
. This is an open access article undertranslation, metabolism, and immune responses [1]. An important mo-
lecular target of this pathway is glycogen synthase kinase 3 (GSK3),
which is phosphorylated and inactivated by Akt [3,4]. The PI3K/Akt/
GSK3 “sub-pathway” so formed (Supplementary Fig. 1) has an impor-
tant role in innate immunity. Speciﬁcally, it is well known to down-
regulate the pro-inﬂammatory cytokine IL-12 and to up-regulate the
anti-inﬂammatory cytokine IL-10 in myeloid cells stimulated with TLR
agonists [5–12]. TLR stimulation is accompanied by PI3K and Akt activa-
tion and therefore inactivation of GSK3, the activity of which inﬂuences
the expression of IL-12 in a positive way and that of IL-10 in a negative
way. In this context, Akt has been shown to inactivated GSK3 both di-
rectly as mentioned above, and indirectly through P70S6 kinase
(P70S6K); P70S6K is activated by themTOR complex 1, in turn activated
downstream of PI3K and Akt [3,11].
In short, through inactivating GSK3, the PI3K/Akt pathway prevents
excessive inﬂammatory responses after TLR activation. For the capacity
of the pathway to downregulate IL-12, pharmacological evidence agrees
with the evidence generated from gene-targeted mice [5,8,9,13–15].
This includes evidenced obtained with wortmannin, the most widely
used PI3K inhibitor, known to be free of the speciﬁcity problems affect-
ing LY294002 in particular [12]. In contrast, for IL-10 upregulation, re-
sults obtained with wortmannin [16,17], often clash with the evidence
based on genetically modiﬁed mice [14,15,18,19]. However, the results
generated using a speciﬁc inhibitor of the catalytic subunit p110δ do
agree with the data from genetically modiﬁed mice [14]. Thus, itthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
214 Á. Pittini et al. / International Immunopharmacology 36 (2016) 213–217seems likely that the effects of wortmannin on other targets, including
non-class I PI3Ks, could explain these disagreements.
Class III PI3K, VPS34, generates phosphatidylinositol 3-phosphate,
PI(3)P [1]. VPS34 is active as part of at least two complexes with differ-
ent cellular localizations and roles [20]. Thus VPS34 regulates mem-
brane trafﬁcking, autophagy, and it is also proposed to participate in
amino acid sensing upstream of mTORC1 activation [20,21]. Whereas
VPS34 is targeted by wortmannin and other pan-PI3K inhibitors such
as 3-methyladenine, speciﬁc inhibitors for this kinase were described
only in the last two years [22–24]. In this study, we make use of these
new inhibitors to explore the impact of VPS34 inhibition on the cytokine
responses of dendritic cells to TLR agonists. Our results help to explain
the paradoxical effects of wortmannin on IL-10 production.2. Materials and methods
2.1. Antibodies and reagents
Antibodies against Akt and phosphorylated Akt (S473) were pur-
chased from Cell Signaling Technology. Antibody to α-tubulin was
from Santa Cruz Biotechnology. Secondary antibodies, anti-IgG and
anti-IgM, both HRP-conjugated, were from Calbiochem and Invitrogen,
respectively. Wortmannin was purchased from Sigma, Akt inhibitor
VIII (Akt VIII) from Merck-Millipore, and GDC-0941 and SB216763
from ApexBio. SAR405 and VPS34IN-1 were purchased from the Divi-
sion of Signal Transduction Therapy (DSTT) Unit at the University of
Dundee. LPS and Pam3CSK4 were purchased from Sigma and
InvivoGen, respectively.2.2. Generation of murine bone-marrow-derived dendritic cells (BMDCs)
BMDCs were obtained by the method of Lutz et al. [25] as described
in detail in [26]. Recombinant mouse granulocyte-macrophage colony-
stimulating factor (GM-CSF) was from PeproTech. All stimuli were
added in medium containing 5 ng/mL GM-CSF.2.3. Immunoblotting
Immunoblotting analysis was performed following standard proce-
dures. BMDCs were lysed in PBS pH 7,2, 0.5% w/v Triton X-100
(Applichem), containing protease and phosphatase inhibitor cocktails
from Santa Cruz Biotechnology. Lysates were resolved on SDS-PAGE
and transferred onto polyvinylidene ﬂuoride membranes from Merck-
Millipore. Membranes were blocked in PBS, 0.1% w/v Tween 20
(Sigma) and 0.5%w/v BSA (Sigma), probed with the corresponding an-
tibodies and developed with the SuperSignal™West Pico Chemilumi-
nescent Substrate (ThermoFisher).2.4. Measurement of cytokines
BMDCs were treated with inhibitors 30 min before stimulation with
TLR agonists. IL-10, IL-12p70, IL-6 and tumor necrosis factor alpha
(TNF-α) were measured in cultured supernatants, after 18 h of
BMDCs stimulation, using ELISA kits from BD Biosciences.2.5. Statistical analyses
The intra-experiment statistical analyses were carried out by
one-way analysis of variance (ANOVA), with a Tukey post-test. The
inter-experiment statistics (i.e. putting together the results of repeated
independent experiments) were carried out by the restricted
maximum-likehood (REML) method [27], also with a Tukey post-test.3. Results and discussion
3.1. Wortmannin causes a paradoxical increase in IL-10 production in
BMDCs stimulated with TLR agonists
Because the PI3K/Akt/GSK-3 sub-pathway is known to regulate the
production of IL-10 and IL-12 in response to TLR agonists in myeloid
cells [5–11], we chose to study how the inhibition of each of these ki-
nases affects the production of IL-10 and IL-12 in BMDCs stimulated
with LPS (Fig. 1). As expected, a speciﬁc inhibitor of GSK-3
(SB216763) increased IL-10 productionwhereas it decreased IL-12 pro-
duction (Fig. 1A). Also as expected, the inhibition of Akt (by Akt inhibi-
tor VIII) decreased IL-10 production and increased IL-12 production
(Fig. 1B). However, the inhibition of PI3Ks by wortmannin, while in-
creasing IL-12 production as expected, did not decrease IL-10 produc-
tion, and it actually increased it, both after stimulation with LPS and
with the TLR2 agonist Pam3CSK4 (Fig. 1C and D). This is similar to the
increase in IL-10 production induced by wortmannin reported previ-
ously in macrophages [19].
3.2. VPS34 inhibition enhances the production of both IL-10 and IL-12 in
BMDCs stimulated with TLR agonists
Since wortmannin is a pan-PI3K inhibitor, we speculated that the
paradoxical increase in IL-10 production caused by this drug may be
due to inhibition of VPS34. In order to investigate this issue, we used
two structurally unrelated inhibitors of this kinase, namely SAR405
and VPS34-IN1 [22,23]. We veriﬁed that the phosphorylation of Akt
(S473) was abrogated by wortmannin, Akt inhibitor VIII and the PI3K
class I-speciﬁc inhibitor GDC-0941, but not by the new VPS34 inhibitors
(Supplementary Fig. 2). The VPS34 inhibitors had only aminor negative
effect on Akt phosphorylation; this is unlikely to be a direct effect on
PI3K class I, since it has been shown that neither inhibitor affects signif-
icantly the activity of PI3K class I at the concentration used in our exper-
iments (1 μM) [22,23]. In contrast to the PI3K class I-speciﬁc inhibitor
(GDC-0941), which caused the expected decrease in IL-10 production,
both VPS34 inhibitors increased IL-10 production in BMDCs stimulated
with either LPS or Pam3SCK4 (Fig. 2A). Simultaneous inhibition of PI3Ks
class I and III (by the combined use of GDC-0941 and SAR405) had as the
net effect an enhancement in IL-10 production. In otherwords, the com-
bination of speciﬁc PI3K class I and III inhibitors imitated the effect of
wortmannin. Hence the paradoxical effect of wortmannin on IL-10 pro-
duction is likely explained by the inhibition of VPS34, which has a neg-
ative effect on this cytokine.
We also evaluated whether the VPS34 inhibitors affect the produc-
tion of IL-12. SAR405 and VPS34-IN1 increased IL-12 production, as
did GDC-0941 (Fig. 2B). The effect of VPS34 inhibition was weaker
than that of PI3K class I inhibition, a difference that may be at least par-
tially explained by the enhanced production of IL-10, known to down-
regulate IL-12 in an autocrine manner [8]. The combination of PI3K
class I and class III inhibition induced a large increase in IL-12 produc-
tion in response to LPS or to Pam3CSK4, suggesting an additive effect
of both classes of PI3Ks on the production of this cytokine.
3.3. VPS34 inhibition enhances the production of further cytokines in
BMDCs stimulated with TLRs agonists
Finally, we assessed whether the effects of VPS34 are speciﬁc to IL-
10 and IL-12, or extend to further cytokines. For this purpose, we ana-
lyzed the production of TNF-α and IL-6 in BMDCs stimulated with LPS
and Pam3CSK4, in the presence of the PI3K class-speciﬁc inhibitors
(Fig. 2C and D). GDC-0941 did not affect the production of TNF-α or
IL-6. This differed from the data obtained by Aksoy et al. [15] using
BMDCs carrying a kinase-dead version of PI3Kδ, which suggests that dif-
ferent PI3K class I isoforms may inﬂuence TNF-α and IL-6 differently.
More importantly, both PI3K class III inhibitors signiﬁcantly increased
Fig. 1.Wortmannin does not affect IL-10 production in TLR-stimulated BMDCs as expected from the anti-inﬂammatory nature of the PI3K-Akt-GSK3 sub-pathway. BMDCswere pretreated
with inhibitors or vehicle (DMSO) for 30minbefore stimulationwith 10ng/mL LPS (a–c) or 200ng/mLPam3CSK4 (d). Eighteen hours later, IL-10 and IL-12p70were quantiﬁedby ELISA in
supernatants. Inhibitors tested were SB216763 (10 μM, for GSK3) (a), Akt I/II (10 μM, for Akt) (b), and wortmannin (100 nM, for PI3K) (c, d). All data are presented as mean ± SD of
triplicate wells. The results shown are representative of 3 independent experiments. Inter-experiment statistics are shown (***, P b 0.001; **, P b 0.01, * P b 0.05), along with intra-
experiment ones (###, P b 0.001; ##, P b 0.01, # P b 0.05).
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We also analyzed the effects of the PI3K inhibitors on the secretion of
the low levels of IL-1β elicited by TLR agonists in the absence of
inﬂammasome activators (Supplementary Fig. 3). The VPS34 inhibitors,
but not the class I-speciﬁc inhibitor, signiﬁcantly increased the produc-
tion of IL-1β induced by LPS; a similar enhancement had been previous-
ly reported in the presence of 3-methyladenine, which inhibits both
PI3K class I and class III [28]. However, the potentiation of IL-1β output
by VPS34 inhibitors was absent when Pam3CSK4 was used as astimulus, suggesting that the situation for this cytokine is different
than for conventionally secreted cytokines.
3.4. Concluding remarks
Taken together our results show that inhibition of VPS34 causes in-
creases in the production of several conventionally secreted cytokines
in BMDCs stimulated with TLR agonists. They also show that this en-
hancement, which affects both pro- and anti-inﬂammatory cytokines,
Fig. 2. PI3K class I and class III inhibitors both enhance the production of proinﬂammatory cytokines in TLR-stimulated BMDCs, but they have opposite effects on the production of IL-10.
BMDCswere pretreatedwith inhibitors or vehicle (DMSO) for 30min before stimulationwith 10 ng/mL LPS or 200 ng/mL Pam3CSK4 as indicated. Inhibitors testedwere GDC-0941 (1 μM,
for PI3K class I), VPS34-IN1 (1 μM, for PI3K class III), SAR405 (1 μM, for PI3K class III), or amixture of GDC-0941 and SAR405 (1 μMeach; only in parts (a) and (b)). Eighteen hours later, IL-
10 (a), IL-12p70 (b), IL-6 (c) and TNF-α (d) were quantitated by ELISA in the supernatants. No signiﬁcant levels of cytokines were detected in BMDCs incubated in media without TLRs
agonist. All data of results are given as means ± SD of triplicate wells. Results are representative of 3 independent experiments. Statistical signiﬁcances are expressed as for Fig. 1.
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inhibiting PI3K class I when an inhibitor targeting both PI3K class I
and class III, such as wortmannin, is used. The mechanism underlying
the observed effect of VPS34 inhibition is not obvious. VPS34 is neces-
sary for TLR9 signaling, which starts in endosomes [29], but this cannot
explain the enhancement of cytokine responses after VPS34 inhibition,
nor explain effects in response to TLR family members (TLR2; for pro-inﬂammatory responses, TLR4) that signal from the cell surface. The
mechanisms underlying our observation may well be complex, as
VPS34 inhibition can be expected to have profound effects on the
basic cellular functions of autophagy and vesicular trafﬁcking [20].
When using 18 h or similarly long endpoints, as it is the case in our
work and many others, such alteration in housekeeping cellular pro-
cesses is likely to result in effects impacting on many cellular functions.
217Á. Pittini et al. / International Immunopharmacology 36 (2016) 213–217Therefore our results do not imply necessarily that VPS34 speciﬁcally
controls the cytokine output of dendritic cells under physiological con-
ditions. However, they do imply that the use of pan-PI3K inhibitors to
explore the functionality of the PI3K pathway carries the risk of a con-
founding general enhancement in the cytokine output of cells as a result
of VPS34 inhibition.
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